Top Performing Drug – Dupixent (April Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Dupixent and prepared a curated analysis report for our readers Dupixent is an interleukin-4 receptor alpha antagonist used for the treatment of multiple indications including atopic dermatitis, asthma, eosinophilic esophagitis, etc. PharmaShots…

BySenior EditorApril 26, 2023

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Shots: The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industry In February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndrome PharmaShots has compiled…

BySenior EditorMarch 23, 2023

INSIGHTS+

Top Performing Drug of 2021 – Darzalex (March Edition)

Shots: The ongoing series of the top-performing drugs of 2021 based on revenue is continued by Darzalex as the top-performing drug for March month Darzalex is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma in combination with different drugs The report summarizes the key features of Darzalex including revenue…

BySenior EditorMarch 21, 2023

INSIGHTS+

Top Performing Drug of 2021 – Trulicity (February Edition)

Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL solution in a single-dose pen Mechanism of Action: GLP-1 receptor agonist First Approval: US (Sep 18, 2014), EU (Nov 25, 2014) Revenue Analysis1 Trulicity is used for the treatment of type 2 diabetes and to reduce the risk…

BySenior EditorFebruary 22, 2023

INSIGHTS+

Top Performing Drug of 2021 – Imbruvica (January Edition)

Active Ingredient: Ibrutinib Dosage Forms & Strengths: Capsules: 70 mg and 140 mg Tablets: 140 mg, 280 mg, 420 mg, and 560 mg Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi) First Approval: US (13 Nov 2013), EU (Oct 2014)  Revenue Analysis Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…

BySenior EditorJanuary 25, 2023

INSIGHTS+

Top Performing Drug of 2021 – Xarelto (November Edition)

Active Ingredient: rivaroxaban Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg Dosage Form: Tablets Mechanism of Action: Factor Xa inhibitors First Approval: US (1 Jul 2011), EU (30 Sep 2008) Revenue Analysis of Xarelto1 Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…

BySenior EditorNovember 24, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in October 2022

The US FDA approved 1 NDAs and 2 BLA in October 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 66 novel products in 2022 In October 2022, the major highlights drugs were Tecvayli’s approval for relapsed or refractory multiple myeloma, Furoscix for congestion in chronic heart…

BySenior EditorNovember 17, 2022

INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…

BySenior EditorSeptember 22, 2022

INSIGHTS+

Top Performing Drug of 2021 – Stelara (August Edition)

Active Ingredients: Ustekinumab Strength: 45 mg/0.5 mL or 90 mg/mL (SC), 130 mg/26 mL (IV) Dosage Form: Injection Mechanism of Action: Interleukin 12 & 23 inhibitor First Approval: US (25 Sep, 2009), EU (16 Jan, 2009) Revenue1 Stelara is the leading blockbuster drug of Johnson & Johnson. Stelara contributed 9.7% of the Company's total revenues for 2021. Stelara up took…

BySenior EditorAugust 25, 2022

VIEWPOINTS

PharmaShots Interview: GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma

In an interview with PharmaShots, Tom Corbridge, Senior Medical Lead at GSK shared his views on the approval of its anti-IL-5 biologic NUCALA (mepolizumab) in a 40 mg pre-filled syringe for appropriate children aged 6 to 11 years old with severe eosinophilic asthma (SEA) Shots: Nucala can now be given by a child’s HCPs or administered…

BySenior EditorMay 4, 2022

Top Performing Drug – Dupixent (April Edition)

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Top Performing Drug of 2021 – Darzalex (March Edition)

Top Performing Drug of 2021 – Trulicity (February Edition)

Top Performing Drug of 2021 – Imbruvica (January Edition)

Top Performing Drug of 2021 – Xarelto (November Edition)

Insights+: The US FDA New Drug Approvals in October 2022

Top Performing Drug of 2021 – Stelara (August Edition)

PharmaShots Interview: GSK’s Tom Corbridge Shares Insights on Nucala as At-Home Treatment Option for Children with Severe Eosinophilic Asthma

Contact US

OUR INFORMATION

FOLLOW US